Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

INDIANAPOLIS, Feb. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and e... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, Ankylosing Spondylitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news